Category: Drug Checking Report
Posted: May 26 2020
Author: CDPE

Results from Samples Checked by Toronto’s Drug Checking Service: May 9 – 22, 2020

Checked Samples by Sample Type

Between May 9 – 22, 2020, 31 samples were checked: 55% (17) were substances and 45% (14) were post-use paraphernalia.

 

Checked Samples by Expected Drug

When a client submits a sample to be checked, they indicate which drug they expect that sample to contain. Of the 31 samples checked between May 9 – 22, 2020:

  • 12 were expected to be fentanyl
  • 4 were expected to be cocaine
  • 4 were expected to be ketamine
  • 4 were expected to be methamphetamine
  • 1 was expected to be crack
  • 6 did not have a stated expected drug

 

Expected Fentanyl Samples

Of the 31 samples checked between May 9 – 22, 2020, 39% (12) were expected to be fentanyl (17% were substances and 83% were post-use paraphernalia).

 

Presence of fentanyl in expected fentanyl samples (12)

  • 8% (1) contained no fentanyl
  • 92% (11) contained fentanyl and other drugs

 

Expected fentanyl samples containing fentanyl and other drugs (11)

Of the 12 samples expected to be fentanyl, 92% (11) contained fentanyl and other drugs. Other drugs found included:

  • 100% (11) of expected fentanyl samples contained caffeine
  • 27% (3) of expected fentanyl samples contained one or more benzodiazepine or benzodiazepine-related drug*:
    • 27% (3) of expected fentanyl samples contained etizolam*
    • 9% (1) of expected fentanyl samples contained flualprazolam*
  • 18% (2) of expected fentanyl samples contained ACHMINACA* (synthetic cannabinoid-related drug)
  • 9% (1) of expected fentanyl samples contained norfentanyl*
  • 9% (1) of expected fentanyl samples contained phenacetin*

 

Other Expected Drug Samples Containing Unexpected Noteworthy Drugs

Of the remaining 19 samples checked between May 9 – 22, 2020, meaning samples that were not expected to be fentanyl, 42% (8) contained one or more unexpected noteworthy drug. Unexpected noteworthy drugs found included:

  • 50% (3) of samples that did not have a stated expected drug contained one or more benzodiazepine or benzodiazepine-related drug*:
    • 50% (3) of samples that did not have a stated expected drug contained etizolam*
    • 17% (1) of samples that did not have a stated expected drug contained flualprazolam*
  • 50% (3) of samples that did not have a stated expected drug contained fentanyl*
  • 33% (2) of samples that did not have a stated expected drug contained ACHMINACA* (synthetic cannabinoid-related drug)
  • 50% (2) of expected cocaine samples contained phenacetin*
  • 25% (1) of expected cocaine samples contained levamisole*

 

*Unexpected noteworthy drug: “Noteworthy drugs” are drugs that are highly potent, linked to overdose or other adverse effects, or may not be desired by some clients. Noteworthy drugs are called out when they are unexpectedly found in checked samples.